Welcome to our dedicated page for Acm Research SEC filings (Ticker: ACMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ACM Research, Inc. filings document the company’s semiconductor process-equipment business, reported operating results, governance matters, and capital-structure events tied to its U.S.-listed parent company and ACM Research (Shanghai), Inc. Forms 8-K furnish quarterly and annual results releases, preliminary revenue and shipment disclosures, subsidiary public-market announcements, and completed changes in ACM’s ownership interest in ACM Shanghai.
Proxy filings cover annual meeting proposals, including director elections and auditor ratification. The filing record also includes disclosures on ACM Shanghai’s STAR Market listing context, shareholder voting matters, material-event reporting, and related governance and ownership information for the company’s operating structure.
ACM Research, Inc. (ACMR) Form 144 notice: The filer intends to sell 30,000 shares of the issuer's common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $900,012.00. The shares reported were acquired and will be paid for by cash on 08/22/2025 via a stock option exercise from the issuer. The filing shows 64,180,965 shares outstanding, lists the proposed sale date as 08/22/2025 on the NASDAQ, and reports no securities sold by the person in the past three months.
Form 144 notice for ACM Research, Inc. (ACMR) shows a proposed sale of 11,152 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $334,560.00. The shares represent a portion of 64,180,965 shares outstanding and an approximate sale date of 08/22/2025. The shares were acquired on 08/22/2025 by stock option exercise from the issuer and paid in cash. The filer reports no securities sold in the past three months and affirms they are not aware of any undisclosed material adverse information.
ACM Research, Inc. reported that its operating subsidiary, ACM Research (Shanghai), Inc., filed a Record of August 2025 Investor Relations Activity with the Shanghai Stock Exchange’s STAR Market. The Shanghai Stock Exchange posted this record on August 15, 2025.
The company furnished an unofficial English translation of this record as Exhibit 99.1 for investors who follow ACM Research’s activities in China. The information, including the exhibit, is being furnished rather than filed, meaning it is not subject to certain liability provisions under U.S. securities laws and is not automatically incorporated into other ACM Research securities filings.
Charles C. Pappis, a director of ACM Research, Inc. (ACMR), was granted a stock option to buy 20,000 shares of Class A common stock at an exercise price of $24.93 per share. The option was granted with an exercise date of 08/12/2025, vests immediately prior to the issuer's 2026 annual meeting subject to continued service, and expires on 08/11/2035. After this transaction, Mr. Pappis beneficially owns 20,000 underlying shares through the option, held directly.
Tracy Liu, a director of ACM Research, Inc. (ACMR), reported acquiring derivative securities on 08/12/2025. The Form 4 shows an option (exercise price $24.93) to acquire 20,000 shares of Class A common stock, recorded as an acquisition on 08/12/2025 and resulting in beneficial ownership of 20,000 shares. The option "will vest and become exercisable immediately prior to the 2026 annual meeting of stockholders," subject to continued service through the vesting date. The filing was submitted by one reporting person and signed on behalf of Ms. Liu by attorney-in-fact Mark McKechnie on 08/14/2025.
Haiping Dun, a director of ACM Research, Inc. (ACMR), reported acquiring a derivative security on 08/12/2025. The Form 4 shows an acquisition of a stock option covering 20,000 shares of Class A common stock with an exercise price of $24.93 and an expiration date of 08/11/2035. Following the reported transaction, the filing lists 20,000 shares beneficially owned directly by the reporting person.
The filing explains the option "will vest and become exercisable immediately prior to the 2026 annual meeting of stockholders," subject to continued service through the vesting date. The Form 4 was signed by an attorney-in-fact on behalf of Haiping Dun on 08/14/2025.